Table 1.

The engagement of aptamer-based nanoformulations in anti-cancer therapy

Type	Nanoformulation	Indication	Reference
Anti-HER2 aptamer (HApt)	Gold nanoparticles	HER-2 positive breast cancer	[207]
CD133 aptamer	Salinomycin-loaded PEGylated PLGA nanoparticles	Osteosarcoma	[208]
CD133 aptamers A15 and EGFR aptamers CL4	Salinomycin-loaded PLGA nanoparticles	Hepatocellular carcinoma	[209]
EGFR-targeting aptamers	Triple-functional pRNA-3WJ nanoparticles	Triple-negative breast cancer	[210]
EpCAM aptamer	Doxorubicin-loaded PEG-PLGA nanoparticles	Non-small cell lung cancer	[211]
Mucin 1 aptamer	Gold nanoparticle-hybridized graphene oxide	Breast cancer	[212]